JCOGP
Journal of Controversies in Obstetrics & Gynecology and Pediatrics

As of January 2023, our "Journal of Controversies Obstetrics & Gynecology and Pediatrics" has been published under the Medihealth Academy to publish all articles, reviews and case reports on Pediatrics, especially in the field of Obstetrics and Gynecology. In order to facilitate the citation of the articles, to take our place in internationally respected indexes and to reach a wider readership, we will pay attention to the fact that our article language is only English in terms of acceptance. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
The importance of CA-125 and clinical markers in ovarian cancer
Abstract
Aims: In this study, considering all the known facts about ovarian cancer; The aim of this study is to retrospectively examine the factors related to the etiopathogenesis, diagnosis and prognosis of ovarian cancer, to determine the population at risk, and to try to catch cancer before it progresses or at an early stage by controlling it more frequently and early.
Methods: A total of 99 patients who were operated for adnexal mass in Dicle University Faculty of Medicine, Department of Obstetrics and Gynecology between 1 January 2011 and 31 December 2020 and whose final pathology resulted as alignant were included in our study. Patients with borderline results were not included in our study. Of these 99 patients age, gravityparity, menopausal status, presence of additional disease, symptoms, CA-125 level, tumor burden, tumor diameter and structure, presence of ascites, presence of implant, lymph node involvement, frozen pathology result, tumor type, stage, complications were investigated.
Results: In this study, the mean age at diagnosis was 51.04 years. It was observed that 55.6% of the patients were postmenopausal. The most common tumor type was identified as epithelial tumors. It has been determined that the patients are mostly in the advanced stage. When the relationship between the stage and the presence of lymph node and ascites fluid was examined, it was observed that lymph node involvement and presence of ascitic fluid increased in advanced stages. It has been observed that the universe progresses as the CA-125 level rises. It has been demonstrated that CA-125 is higher in patients with residual tumors. In addition, CA-125 levels were higher in patients with lymph node involvement than in those without involvement, in patients with bilateral tumours than in those with unilateral tumours, in patients with ascites than in those without ascites, and in epithelial type tumours than in other tumour types.
Conclusion: Although scientific research has been carried out on many markers for ovarian cancer, especially Ca-125, it is difficult to detect it at an early stage since routine ovarian cancer screening is not possible under today’s conditions. Even though it is not specific, if some symptoms such as abdominal pain are present in older women, considering ovarian cancer among the preliminary diagnoses may help detect more patients at an early stage.

Keywords : CA-125, ovarian cancer, postmenopausal, lymph node, acid fluid

Download Article


1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovariancancer in the world: epidemiology and risk factors. Int J WomensHealth. 2019;30:(11)287-299.
2. Torre LA. Ovarian cancer statistics. Cancer J. Clin. 2018;68:284-296.
3. Van Calster. Evaluating the risk of ovarian cancer before surgeryusing the ADNEX model to differentiate between benign, borderline,early and advanced stage invasive, and secondary metastatic tumours:prospective multicentre diagnostic study. Bmj. 2014;15:349.
4. Shan D, Cheng S, Ma Y, Peng H. Serum levels of tumor markers andtheir clinical significance in epithelial ovarian cancer. Zhong Nan DaXue Xue Bao Yi Xue Ban. 2023;48(7):1039-1049.
5. Arezzo F, Loizzi V, La Forgia D, et al. The role of ultrasound guidedsampling procedures in the diagnosis of pelvic masses:a narrativereview of the literature. Diagnostics. 2021;11(12):2204. .
6. Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of theovary, fallopian tube, and peritoneum: 2021 update. Int J GynaecolObstet. 2021;1:61-85.
7. M. A. Roett and P. Evans, “Ovarian cancer: an overview,” Am FamPhysician. 2009;6:609-616.
8. T. Edirne, F. Soylu, D. Güldal, and L. Çamlı. Over tümörlerininepidemiyolojik özellikleri, Türk Aile Hek Derg. 2002;6(1):24-28.
9. Lurie PJ. Thompson KE, McDuffie ME, Carney MT. Goodman. Prediagnostic symptoms of ovarian carcinoma: a case-control study.Gynecol Oncol. 2009;114(2):231-236
10. Givens V, Mitchell GE. Diagnosis and management of adnexal masses.Am Fam Physician. 2009;80:815.
11. Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterizationof prediagnostic symptoms among primary epithelial ovarian cancercases and controls. Gynecol Oncol. 2003;90(1):75-82
12. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: areview. Cancer Biol Med. 2017;14(1):9-32.
13. Yoshida H, Tanaka H, Tsukada T, et al. Diagnostic discordance inintraoperative frozen section diagnosis of ovarian tumors: a literaturereview and analysis of 871 cases treated at a Japanese cancer center.Int JSurg Pathol. 2021;29(1):30-38.
14. F. Zaiem, Deirawan H. Accuracy and reproducibility of frozen sectiondiagnosis ino tumors: a 10-year experience at a tertiary cancer center.Arch Pathol Lab Med. 2022;146(5):626-631
15. De Decker K. Borderline ovarian tumor frozen section diagnoses withfeatures suspicious of invasive cancer: a retrospective study. J OvarianRes.2021;14(1):139.
16. Özkan, NT, Kadıoğlu N, Timur B, Meydanlı MM. Plazma D Dimerdüzeyinin yüksek dereceli seröz over kanseri olan olgularda prognostikverilerle olan ilişkisi.Gümüşhane Üniversitesi Sağlık Bilimleri Derg.2022;11(1):153-157.
17. Başer Açıkgöz R, Harma M. Pelvik kitlelerin malignite riskideğerlendirilmesinde kanser antijeni 125 (Ca 125), human epididymisprotein 4 (HE4), soluble mesothelin-related protein (SMRP) vefolat reseptör alfa (FOLRα) ölçümünün yeri. Med J West Black Sea.2018;2(3):208-16.
18. S. Ivanov. Epithelial ovarian cancer--preoperative assessment ofCa 125 levels as an independent prognostic factor. Akush Ginekol.2003;42(3)16-19
19. Modarres-Gilani F. Ghaemmaghami S. Ansaripoor MSF. CANpreoperatıve Ca-125 predıct resectabılıty of tumor in patıents withadvanced epıthelıal ovarıan carcınoma? Acta Med. 2004;1:419-423
20. Chi DS. What is the optimal goal of primary cytoreductive surgery forbulky stage IIIC epithelial ovarian carcinoma (EOC). Gynecol Oncol.2006;103(2)559-564
21. Li AJ, Madden AC, Cass I, et al. The prognostic significance ofthrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol.2004;92(1):211-214.
22. Aletti GD. Aggressive surgical effort and improved survival inadvanced-stage ovarian cancer. Obstet Gynecol. 2006;107(1):77-85.
23. Powless CA, Aletti GD, Bakkum Gamez JN, Cliby WA. Risk factorsfor lymph node metastasis in apparent early-stage epithelial ovariancancer: implications for surgical staging.Gynecol Oncol.2011;122:536-540
24. Heitz F, Harter P, Ataseven B, et al. Stage- and histologic subtype-dependent frequency of lymph node metastases in patients withepithelial ovarian cancer undergoing systematic pelvic and paraaorticlymphadenectomy.Ann Surg Oncol.2018;25:2053-2059.
25. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors oflymph node metastases in epithelial ovarian cancer.Int J GynecolCancer.2007;17:1238-1244.
26. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. <em>Nat. Rev. Cancer</em>. 2013;13(4):273-282.
27. Ford CE, Werner B, Hacker NF, Warton K. The untapped potential of ascites in ovarian cancer research and treatment. <em>Br. J. Cancer</em>. 2020;123:9-16.
Article available in :
Volume 2, Issue 3, 2024
Page : 58-63
https://doi.org/10.51271/JCOGP-0036
Article Information
Received : 09 Tem 2024
Accepted : 30 Tem 2024
Published : 30 Tem 2024
Corresponding Author :

Mulaim Sizer: Department of Obstetrics and Gynecology, Batman Training and Research Hospital, Batman, Turkiye

[email protected]
Citation : Alkılıç Dönmez D, Sizer M, Sunar N, İçen MS, Çirkin Tekeş G. The importance of CA-125 and clinical markers in ovarian cancer. J Controv Obstetr Gynecol Ped. 2024;2(3):58-63.

Read: 288
Cited: 0
Download : 52
_Footer